JP2020536887A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536887A5
JP2020536887A5 JP2020520007A JP2020520007A JP2020536887A5 JP 2020536887 A5 JP2020536887 A5 JP 2020536887A5 JP 2020520007 A JP2020520007 A JP 2020520007A JP 2020520007 A JP2020520007 A JP 2020520007A JP 2020536887 A5 JP2020536887 A5 JP 2020536887A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
composition according
patient
ddr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020520007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536887A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/055174 external-priority patent/WO2019075032A1/en
Publication of JP2020536887A publication Critical patent/JP2020536887A/ja
Publication of JP2020536887A5 publication Critical patent/JP2020536887A5/ja
Withdrawn legal-status Critical Current

Links

JP2020520007A 2017-10-13 2018-10-10 Parp阻害剤およびpd−1系結合アンタゴニストの組合せ Withdrawn JP2020536887A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762572024P 2017-10-13 2017-10-13
US62/572,024 2017-10-13
US201862697587P 2018-07-13 2018-07-13
US62/697,587 2018-07-13
PCT/US2018/055174 WO2019075032A1 (en) 2017-10-13 2018-10-10 COMBINATION OF A PARP INHIBITOR AND A PD-1 AXIS BINDING ANTAGONIST

Publications (2)

Publication Number Publication Date
JP2020536887A JP2020536887A (ja) 2020-12-17
JP2020536887A5 true JP2020536887A5 (cg-RX-API-DMAC7.html) 2021-09-02

Family

ID=64049735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020520007A Withdrawn JP2020536887A (ja) 2017-10-13 2018-10-10 Parp阻害剤およびpd−1系結合アンタゴニストの組合せ

Country Status (13)

Country Link
US (1) US20200254091A1 (cg-RX-API-DMAC7.html)
EP (1) EP3694551A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020536887A (cg-RX-API-DMAC7.html)
KR (1) KR20200071097A (cg-RX-API-DMAC7.html)
CN (1) CN111225685A (cg-RX-API-DMAC7.html)
AU (1) AU2018347331A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020006371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078806A1 (cg-RX-API-DMAC7.html)
IL (1) IL273994A (cg-RX-API-DMAC7.html)
MX (1) MX2020003361A (cg-RX-API-DMAC7.html)
RU (1) RU2020113246A (cg-RX-API-DMAC7.html)
TW (1) TW201922288A (cg-RX-API-DMAC7.html)
WO (1) WO2019075032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019006504A2 (pt) * 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TWI852940B (zh) * 2018-09-04 2024-08-21 美商泰沙羅公司 治療癌症之方法
JP7805005B2 (ja) * 2019-12-31 2026-01-23 フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド 腫瘍治療の医薬組み合わせとその使用
US20230338521A1 (en) * 2020-05-04 2023-10-26 Merck Sharp & Dohme Llc Methods of treating cancer using a combination of a pd-1 antagonist, a chemoradiation therapy and a parp inhibitor
EP4313034A1 (en) * 2021-03-24 2024-02-07 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202600137A (zh) 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用parp抑制劑的治療作為預測性生物標記之tmprss2-erg和rbi及使用parp抑制劑之治療方法
WO2026078615A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2026078619A1 (en) 2024-10-09 2026-04-16 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUE035295T2 (en) 2008-08-06 2018-05-02 Medivation Technologies Inc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
CA2787844C (en) 2010-02-03 2019-08-27 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
MX340319B (es) 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
CN103282365B (zh) 2010-10-21 2017-12-29 麦迪韦逊科技有限公司 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
EP3066084A1 (en) 2013-11-07 2016-09-14 Medivation Technologies, Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
US10570202B2 (en) * 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
BR112017000672A2 (pt) * 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
EP3227337A1 (en) * 2014-12-05 2017-10-11 F. Hoffmann-La Roche AG Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
KR20170132171A (ko) * 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 pd­1 / pd­l1 저해제
EP3303397A1 (en) * 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CN108883115A (zh) 2015-10-26 2018-11-23 麦迪韦逊科技有限责任公司 用parp抑制剂治疗小细胞肺癌

Similar Documents

Publication Publication Date Title
Wu et al. Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis
JP2016501213A5 (cg-RX-API-DMAC7.html)
JP2023546009A5 (cg-RX-API-DMAC7.html)
JP2022536854A5 (cg-RX-API-DMAC7.html)
RU2016151303A (ru) Применение эрибулина в лечении рака
He et al. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking
RU2020113246A (ru) Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2017516802A5 (cg-RX-API-DMAC7.html)
Lu et al. Polymeric micellar paclitaxel (Pm-Pac) prolonged overall survival for NSCLC patients without pleural metastasis
JP2018513155A5 (cg-RX-API-DMAC7.html)
JP2025504278A5 (cg-RX-API-DMAC7.html)
He et al. Changing patterns of neoadjuvant therapy for locally advanced rectal cancer: A narrative review
RU2019134769A (ru) Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения
Qureshi et al. Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine
Ozdemir et al. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients
Liu et al. Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study
Wang et al. RATIONALE 307: Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
Modesto et al. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients
Chu et al. A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Yasenchak et al. 397 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)
Lin 178P Targeting mitochondria EGCG nanoparticles synergistically regulate immunogenic cell death and copper death to improve the anti-tumor efficacy of breast cancer
Iovita et al. 117P Targeted compound screening for the exploration of actionable vulnerabilities in LUSC
Hu et al. 115P Liposomal irinotecan (HR070803) plus fluorouracil and bevacizumab as second-line treatment in patients with advanced colorectal cancer: Cohort A results from a phase II trial
Bahl et al. 112P Evaluation of afatinib in recurrent and metastatic head neck cancers